SILO PHARMA, INC.
Ownership & governance
Executives 3Directors 4Avg age 59Avg tenure 6.6y
EW
Eric Weisblum
Chief Executive Officer
Age 57Since 2015-11-26Profile →
+6
Executives3
EW
Eric Weisblum→
Chief Executive Officer
Age 57Since 2015-11-26
DR
Daniel Ryweck→
Director of Finance/CFO
Age 62Since 2022-09-26
JK
James Kuo
Chief Tech/Sci/R&D Officer
Age 60Since 2022-08-31
Board of directors4
Shareholders5
| Name | Stake | Shares |
|---|---|---|
| AdvisorShares Investments LLC | 0.3324 % | 44,265 |
| Eric Weisblum | 0.1086 % | 14,462 |
| Geode Capital Management LLC | 0.0901 % | 12,002 |
| G1 Execution Services LLC | 0.0314 % | 4,186 |
| Jane Street Group LLC | 0.0224 % | 2,984 |
Catalog · 2026-07-09
Proxy officers8
| Name | Role | Since | Shares |
|---|---|---|---|
| Eric Weisblum | Chairman | 2015-11-26 | - |
| Daniel Ryweck | Director or executive officer | — | 3,667 |
| Jeff Pavell | Director/Board Member | 2022-09-26 | - |
| Jeff Pavell | Director or executive officer | 2022-09-01 | 3,333 |
| Kevin Muñoz | Director/Board Member | 2020-09-30 | - |
| Kevin Muñoz | Director or executive officer | 2020-10-01 | 3,562 |
| Wayne D. Linsley | Director or executive officer | 2020-01-01 | 3,562 |
| Wayne Linsley | Director/Board Member | 2020-01-15 | - |
Proxy · as of 2026-08-14
Institutional (13F)
Loading Form 13F holders…
Fund membership
Loading fund baskets…
Street consensus
Consensus none
Broker actions1
| Firm | Action | To | Target | Date |
|---|---|---|---|---|
| Laidlaw & Co. | Initiated | Buy | 10 | 2023-08-28 |
Firm rows and rating mix from Yahoo Finance; mean target is Yahoo’s aggregate until OpenFilings derives consensus from broker rows.